Yazar "Lechner-Scott, J." için listeleme

Toplam kayıt 7, listelenen: 1-7

Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Sharmin, S.; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Lechner-Scott, J. (Sage Publications Ltd, 2019)

…
Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; Wiendl, H.; Lechner-Scott, J. (Sage Publications Ltd, 2015)

…
Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

Kalincik, T.; Brown, J. W.; Robertson, N.; Willis, M.; Scolding, N.; Pearson, O.; Lechner-Scott, J. (Sage Publications Ltd, 2016)

…
Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak, N.; Lugaresi, A.; Alroughani, R.; Lechner-Scott, J.; Slee, M.; Havrdova, E.; Rio, M. E. (Sage Publications Ltd, 2015)

…
Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

De Brouwer, E.; Peeters, L.; Becker, T.; Altintas, A.; Soysal, A.; Van Wijmeersch, B.; Lechner-Scott, J. (Sage Publications Ltd, 2019)

…
Predicting long-term sustained disability progression in multiple sclerosis

Sharmin, S.; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Lechner-Scott, J. (Sage Publications Ltd, 2019)

…
The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown, J. W. L.; Lugaresi, A.; Horakova, D.; Havrdova, E.; Jokubaitis, V.; Lechner-Scott, J.; Hutchinson, M. (Sage Publications Ltd, 2017)

…